Nama's AI scorecard currently rates Septerna Hold (4.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does SEPN report earnings?

Septerna's next scheduled report is on Nov 9, 2026. Analysts expect EPS of -$0.40.

What is the SEPN price target?

The median analyst price target from 9 analysts is $51.00, with a range of $48.00 – $62.00.

Is SEPN Shariah compliant?

Nama's AAOIFI-style screen reads Septerna as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Septerna (SEPN)

Healthcare · Biotechnology · NASDAQ

Septerna (SEPN) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $2.28B and a free-cash-flow yield of 5.1%. Over the most recent reported fiscal year, revenue grew 4174.5%. Nama's AI scorecard rates it Hold, 4.8 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Hold · 4.8/10

The sections balance. As of Nov 7, 2026.

Momentum

Leading · +91.5% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-4.4%

How far the last close sits under the highest price of the past five years.

Market cap	$2.28B
Trailing P/E	—
Price / book	5.8
Price / sales	23.0
FCF yield	5.1%
Dividend yield	—
Gross margin	100.0%
Operating margin	-63.0%
Net margin	-24.5%
Revenue growth (YoY)	+4174.5%
Revenue growth (3-yr annual)	—
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	2.3
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

SEPN earnings

Next report: Nov 9, 2026 (Q3 2026, EPS estimate -$0.40). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Aug 10, 2026	-$0.29	-$0.49	+40.8%	$26.75M
Q1 2026	May 11, 2026	-$0.19	-$0.44	+56.8%	$26.52M
Q4 2025	Mar 9, 2026	-$0.24	-$0.22	-9.1%	$24.12M
Q3 2025	Nov 10, 2025	-$0.10	$0.79	-112.7%	$21.50M

SEPN analyst price target

Median target $51.00 from 9 analysts, ranging $48.00 – $62.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live SEPN data on Nama Insights →

SEPN FAQ

Is SEPN a buy?: Nama's AI scorecard currently rates Septerna Hold (4.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does SEPN report earnings?: Septerna's next scheduled report is on Nov 9, 2026. Analysts expect EPS of -$0.40.
What is the SEPN price target?: The median analyst price target from 9 analysts is $51.00, with a range of $48.00 – $62.00.
Is SEPN Shariah compliant?: Nama's AAOIFI-style screen reads Septerna as Not Shariah Compliant. At least one of the three ratios or the industry test failed.